Cancer remains one of the most significant global health challenges, requiring precision medicine approaches to improve treatment outcomes. SolidTumorCheck+, powered by Next-Generation Sequencing (NGS), provides a comprehensive genomic profiling (CGP) solution to identify actionable mutations, enabling oncologists to tailor treatments for cancer patients based on their unique tumor genetics. This FDA-approved assay (IVD) serves as a companion diagnostic (CDx) to guide the selection of targeted therapies and immunotherapies for patients with solid tumors, in alignment with regulatory-approved drug indications and professional oncology guidelines.
Why Choose SolidTumorCheck+ Comprehensive?
✅ FDA-approved & clinically validated
✅ Covers 517 DNA & 24 RNA fusion genes
✅ Identifies key biomarkers for targeted therapies & immunotherapy
✅ Provides critical TMB scoring for immunotherapy response assessment
✅ Fast turnaround (10 days) for rapid clinical decision-making
For oncologists, molecular pathologists, clinical researchers and Cancer institutes, SolidTumorCheck+ is an essential tool for delivering precision cancer care in today’s evolving oncology landscape.
It sequences over 517 genes known to be relevant to cancer treatment and assesses essential immunotherapy (IO) biomarkers, providing oncologists with a comprehensive view to devise tailored treatment plans for their patients. Genomic Testing that Facilitates the Identification and Treatment of Cancer.
500+ solid tumor related genes with broad coverage of key guidelines and clinical trials for multiple solid tumor types.
You can expect results in approximately three weeks, facilitated by either manual or automated workflows that encompass library preparation, sequencing, and data analysis.
Sensitivity of 98.91% Specificity >99.99% using Orthogonal methods, Including DNA and RNA. Accurately measures TMB, MSI, SNVs, INDELs, CNVs, structural variations, and gene fusions.
Comprehensive Pan-Cancer Panel High-Throughput includes key guideline biomarkers for multiple cancer types, plus pan-cancer biomarkers such as MSI, NTRK1-3, and TMB.
AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, FGFR1, FGFR3, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, RET, TP53
BRAF, CTNNB1, GNA11, GNAQ, KIT, MAP2K1, NF1, NRAS, PDGFRA, PIK3CA, PTEN, TP53
AKT1, BRAF, HRAS, KRAS, MET, MLH1, MSH2, MSH6, NRAS, PIK3CA, PMS2, PTEN, SMAD4, TP53
BRAF, BRCA1, BRCA2, KRAS, PDGFRA, FOXL2, TP53
AKT1, AR, BRCA1, BRCA2, ERBB2, FGFR1, FGFR2, PIK3CA, PTEN
BRAF, KIT, KRAS, MET,MLH1, PDGFRA, TP53
MSH6, PMS2, TSC1
ALK, APC, BRAF, CDK4, CTNNB1, ETV6, EWSR1, FOXO1, GLI1, KIT, MDM2, MYOD1, NAB2, NF1, PAX3, PAX7, PDGFRA, PDGFRB, SDHB, SDHC, SMARCB1, TFE3, WT1
Advanced interpretation technology to deliver timely and more accurate variant identification.
Relevant treatment options and the most precise clinical results, all in a physician-ready report. This technology is backed by a comprehensive knowledge-base and a powerful rules engine that takes many disparate inputs from our knowledge- base and distills them into concise interpretations and connections supporting evidence.
With over 350,000 rules in place, characteristics of patient variants are leveraged to surface the most optimal treatment possibilities.
PreCheck offers a range of genetic tests designed for various conditions. Each test comes with clear follow-up recommendations, enabling healthcare providers to make personalized decisions based on your genetic profile.
latest announcements and stay updated on our most recent developments.
.svg)
